The Non-Financial Ledger: What Money Can’t Measure

Picture an older person — sixty-something, maybe older — who has been living with knee pain or peripheral neuropathy for years. They’ve tried the medications. Maybe they’ve been told surgery is their only real option, but they can’t afford the downtime, or they’re scared, or their doctor has said the risks aren’t worth it. They are not naive. They are tired and in pain and have every reason to want something to work.

Then a postcard arrives in the mail. Or a Facebook ad. Or a TV commercial between the evening news and the weather. The language is clinical enough to sound credible. “FDA-approved.” “Clinically proven.” “80% success rate.” “In as little as one treatment.” The seminar is free — a “lunch and learn.” There’s a doctor presenting. He has credentials listed. The room has other people in it who have the same aches and the same hope.

You sign up. You pay $5,000 per joint — out of pocket, because this isn’t covered by insurance. Maybe you pay for two joints. Maybe your spouse does too. You put it on a credit card, or you pull from savings, or you ask your adult child not to worry about it. You go back for follow-ups because you were told you might not feel it right away. You don’t feel better. You feel exactly the same, maybe worse, because now you’ve spent money you don’t have on something that was never going to help you — because the people who sold it to you knew, or should have known, that there was no credible evidence it ever worked on anyone.

This is not an abstract harm. The court record names 485 consumers who purchased treatments from just the Georgia clinic operation between 2017 and 2019. Three hundred and thirty-five of them were sixty years old or older. These were not wealthy speculators on experimental medicine. These were ordinary people in pain, specifically targeted because they are the demographic most likely to suffer from the conditions advertised — osteoarthritis, neuropathy, joint degeneration — and most likely to be desperate enough to pay cash for hope.

And while those 485 people were being treated in Canton, Georgia, the same lies were being packaged into binders and email templates and PowerPoint decks and shipped to clinics across the country. Each new clinic that bought the consulting package became a new place where more people in more cities could hand over $5,000 for an injection that the country’s leading stem cell biologists agree has no proven benefit for any of the conditions claimed.

The companies eventually went bankrupt. Peyroux and Detelich still hold interests in other healthcare companies. The 335 seniors who paid up to $10,000 or more from their fixed incomes do not get that money back from a bankruptcy filing. They also do not get back the months they spent hoping this would be the thing that finally worked. That is what lives in the space the dollar figures don’t cover.

Legal Receipts: What They Said and What It Proves

The court record is dense with direct quotes from ads, training videos, email templates, and depositions. These are not interpretations. This is what they actually wrote and said.

“OUR . . . STEM CELL TREATMENTS CAN PROVIDE REMARKABLE IMPROVEMENT WHEN OTHER TRADITIONAL MEDICAL PROCESSES HAVE FAILED OR HAD LIMITED EFFICACY.” — Superior Healthcare clinic website, admitted into evidence as Doc. 96-24.

• This claim was displayed publicly to prospective patients. It directly implies the treatment succeeds where medicine fails, with no scientific evidence to support it. The FTC’s expert found zero competent clinical evidence that these injections treat any orthopedic condition. The defendants did not challenge that finding.
• The same website stated that “stem cells can be used to treat nearly any type of condition caused by injury or degeneration” — an unqualified, sweeping medical claim with no substantiation in peer-reviewed literature.

“It only takes one stem cell treatment to reduce or eliminate your knee pain without prescription medications and without surgery. In fact, many patients start experiencing relief from their pain immediately after the treatment.” — Superior Healthcare TV commercial, admitted into evidence as Doc. 78-6.

• This is a direct efficacy claim broadcast on television. It promises pain elimination in a single session. It also claims immediate post-treatment relief. Neither claim was supported by any clinical trial data, according to the FTC’s expert Dr. Sean Morrison.
• The same ad was one of many TV spots targeting people suffering from neuropathy — a nerve condition causing numbness, burning, and pain in extremities — for which the defendants had no evidence of efficacy whatsoever.

“Superior Healthcare is now offering painless, FDA approved ‘Regenerative Injection Therapy’ for arthritic and/or degenerative conditions.” — SCIA sample email template for client clinics, Doc. 76-23, distributed nationally to healthcare providers.

• The FDA submitted a letter and affidavit to the court confirming it never reviewed or approved the Physicians Business regenerative medicine compliance training or treatment program. The FTC submitted a declaration confirming the same for FTC approval. This advertisement was factually, verifiably false.
• This template was given to client clinics to send to their own patient lists. The defendants were not just lying to consumers directly; they were manufacturing and distributing the lie to be replicated by dozens of clinics they had never even met.

“There are certainly some research and things like that that I can provide to you that are published studies in well-known journal articles. However, the question you really should be asking me is . . . how many people and what results have you seen in people with similar knee conditions to me. . . . Over the past few years that we’ve done this, we have treated hundreds of patients with knee conditions with amazing results. So the level of degeneration you have in your knee makes you a really good candidate for this procedure. And I feel very confident in telling you that this is going to be a positive outcome for you.” — Objection Training Video, Pls. Ex. 470, a Physicians Business coaching session role-playing how to respond to patients who ask for scientific data.

• This is the sales override playbook. When a patient asks the single most important question — is there research? — staff were trained to redirect them away from science and toward anecdote. The script acknowledges that research exists but actively steers the conversation away from it.
• The phrase “I feel very confident in telling you that this is going to be a positive outcome for you” constitutes a medical prognosis delivered as a closing technique in a sales roleplay, directed at consumers with no supporting clinical basis. The person being trained here is a clinic employee whose job title, per another SCIA document, was “case manager” with a purpose to “ensure the public and patients are sufficiently enlightened to purchase stem cell therapy.”

“Learn the only FDA approved regen[erative] med[icine] systems that get results!” and “Best systems to ensure 5 to 10 K per case” and “Cellular Hope Institute – Your private personal advanced Regen[erative] Med[icine] treatment Hospital in Cancun, Mexico . . . . Learn our ultra smooth process of preferring patients to the cancun[sic] center [and] Legal documents so that you can receive 20% of all funds collected without any risk.” — Marietta Seminar Agenda, Doc. 77-25, a 2021 Physicians Business event featuring both Peyroux and Detelich as speakers.

• This agenda item documents that as late as 2021 — three years after the FTC had already begun investigating, and after both companies had filed for bankruptcy — Peyroux and Detelich were still running seminars teaching other clinic owners how to make $5,000 to $10,000 per patient and how to refer patients to a treatment facility in Mexico with a 20% finder’s fee structure.
• The referral-to-Mexico component suggests the operation was not winding down when confronted with legal exposure; it was diversifying and expanding internationally. The “without any risk” language refers to the clinic owner’s legal and financial risk in the referral arrangement, not the risk to the patient receiving unproven treatment in another country.

“there is no competent and reliable scientific evidence that stem cell therapy: 1) cures, treats, or mitigates orthopedic conditions, including osteoarthritis, arthritis, neuropathy, plantar fasciitis, joint pain, and pain resulting from injuries or aging; or 2) is comparable or superior to surgery, steroid injections, and painkillers in curing, treating, or mitigating orthopedic conditions.” — Expert Report of Dr. Sean Morrison, Doc. 78-22 ¶ 19, filed in support of the FTC’s motion for summary judgment.

• Dr. Morrison is the Howard Hughes Medical Institute Investigator and former Director of the University of Michigan Center for Stem Cell Biology. He has published over 140 peer-reviewed articles and was elected President of the International Society for Stem Cell Research. He reviewed every product the defendants administered and every clinical study they could have cited.
• The defendants did not challenge his opinions. They offered no competing expert. They cited no clinical studies. The court found this rendered the lack of scientific substantiation entirely undisputed. The ads claimed cures. The science says: nothing. The defendants never disputed that gap.

Societal Impact Mapping: The Damage Beyond the Courtroom

Public Health

The medical harm embedded in this scheme is structural. Every patient who received an unproven injection instead of evidence-based treatment experienced a delay in real care.

• The FTC’s expert found no competent clinical evidence that the injected products — derived from birth tissue, amniotic fluid, Wharton’s jelly, umbilical cord blood, and similar biological materials — treat osteoarthritis, neuropathy, joint pain, plantar fasciitis, COPD, Parkinson’s disease, multiple sclerosis, or congestive heart failure. All of these conditions were advertised on clinic websites and lecture materials. Patients with progressive conditions like Parkinson’s or MS who opted for these injections over legitimate clinical pathways lost time that cannot be recovered.
• The scheme specifically promoted stem cell therapy as superior to surgery, steroid injections, and pain medications. For a patient with severe osteoarthritis who might have benefited from surgical intervention, deferring that surgery based on false advertising about a competing treatment can result in significantly worse outcomes — increased joint damage, reduced mobility, and deeper chronic pain over time.
• The products used were not FDA-regulated drugs administered under clinical protocols; they were biologics injected at chiropractic clinics and satellite locations where Peyroux’s companies paid flat fees to doctors and medical staff per injection. Patients receiving biologics outside regulated clinical frameworks face infection risk, immune response risk, and the risk of unlicensed product contamination — risks they were not being told about because the marketing was focused exclusively on miraculous benefit claims.
• Across the network of client clinics that Physicians Business and SCIA supplied, hundreds or thousands of additional patients received the same unsubstantiated treatments promoted with the same fake FDA-approval materials. The case record focuses on one clinic’s 485 patients. The national scale of the consulting operation means the true patient count is significantly larger and remains undocumented in full.

Economic Inequality

This operation functioned as a wealth extraction machine specifically engineered to target older Americans on fixed or limited incomes who are statistically the most likely to suffer chronic joint and nerve pain.

• Treatments were priced at approximately $5,000 per joint with no insurance coverage, cash only. A patient with bilateral knee pain and peripheral neuropathy could easily face a $15,000 or $20,000 treatment proposal at a single seminar — pushed by sales staff trained specifically to “handle objections” when the patient hesitated about cost. One Physicians Business seminar literally included a session titled “How to resolve a knee condition with certainty in just 1-2 treatments – The secret to getting $5,000-$10,000 case fees paid in cash.”
• Of the 485 Superior Healthcare patients between 2017 and 2019, 335 were age 60 or older. That is 69% of the patient base. The targeting of seniors was structural: the conditions advertised (arthritis, neuropathy, joint degeneration) disproportionately affect older adults, and the seminar marketing through postcards, community venues, and TV commercials was optimized for that demographic. Clinics were coached to market to “churches or clubs” — community anchors for exactly this age group.
• The “exclusivity membership” model offered to client clinics — where a clinic paid SCIA up to $4,500 per month for territorial protection — demonstrates that the consulting operation was run like a franchise scam layered on top of the patient-facing scam. Clinic owners, many of them chiropractors looking for new revenue streams, also paid for a product (a validated stem cell consulting system) that was built on fabricated science. Their $13,500 annual fees to Physicians Business bought them tools for fraud, not medicine.
• Total gross revenue generated by the entire common enterprise from 2015 to 2022 was $18,403,116.14. Every dollar of that came from people who were deceived. None of it is being recouped in this proceeding because monetary relief under Section 13(b) of the FTC Act was eliminated by the Supreme Court in 2021 (AMG Capital Management v. FTC). The State of Georgia can pursue civil penalties and restitution under state law, but federal consumer restitution — the mechanism that would have actually returned money to patients — is gone.

The “Cost of a Life” Metric

What Now? Permanent Injunction Incoming — But the Work Isn’t Done

Summary judgment has been granted. The court found all five counts proven against all defendants. What comes next is a permanent injunction and Georgia civil penalties — but the structural conditions that made this possible are still in place.

The Named Defendants

• Steven D. Peyroux — Licensed chiropractor, 100% owner and officer of all three corporate defendants. Currently holds interests in multiple other healthcare companies. A permanent injunction from this court will cover future deceptive health advertising, but his existing healthcare interests are not automatically shut down by this ruling.
• Brent J. Detelich — Co-founder and former president of SCIA. Chiropractic license already revoked due to federal felony conviction. Still participated in sales training events as recently as 2021. Also holds interests in other healthcare companies per the court record.
• Physicians Business Solutions, LLC — The only corporate defendant that did not file for bankruptcy. It remains operational as of the court filing date.

Watchlist: Regulatory Bodies With Jurisdiction

• FTC (Federal Trade Commission) — The primary federal plaintiff. This case will result in a permanent injunction. The FTC Bureau of Consumer Protection handles complaints about deceptive health product advertising. File at ftc.gov/complaint.
• Georgia Attorney General’s Office — Co-plaintiff in this case under the Georgia Fair Business Practice Act. Has authority to impose civil penalties and seek restitution for Georgia consumers. Contact through law.georgia.gov.
• FDA (Food and Drug Administration) — Has authority over the biological products used in these injections. The FDA submitted an affidavit in this case confirming it never approved these programs. The FDA’s MedWatch program accepts reports of misleading drug or device advertising.
• State Medical and Chiropractic Licensing Boards — In every state where a client clinic received Physicians Business or SCIA consulting materials, the treating practitioners were subject to state licensing authority. Those states’ boards remain the most direct regulators of individual practitioners who deployed these materials on patients.
• DOJ (Department of Justice) / U.S. Attorney Offices — Detelich’s existing federal felony conviction means DOJ oversight of his activities in federally regulated commerce is a relevant channel. Any future potential criminal referrals related to ongoing deceptive health marketing would route through DOJ.

What You Can Do

• If you or someone you know paid for stem cell injections at a clinic marketed through SCIA or Physicians Business materials, document the experience: dates, amounts paid, the clinic name, and copies of any advertising received. File a complaint with the FTC at ftc.gov/complaint and with your state attorney general. These records build the evidentiary record for civil penalty calculations and restitution proceedings.
• If you are a healthcare provider or clinic owner who purchased consulting services from SCIA or Physicians Business, you may have paid for fraudulent consulting materials. You may have grounds for your own civil claim. Consult a consumer protection attorney. The FTC’s actions in this case establish that the materials themselves were means and instrumentalities of deception.
• Organize locally around senior consumer protection. Organizations like AARP and local senior advocacy groups can use this case as a template for community education. The targeting of older adults with fake medical cures is a documented, repeated, and profitable industry practice. Peer education — neighbor to neighbor, family to family — is the first line of defense against the next version of this scheme.
• Push for restoration of FTC restitution authority. The Supreme Court’s 2021 AMG decision stripped the FTC of its ability to return money directly to defrauded consumers. Congress can restore this authority through legislation. Contact your federal representatives. Without monetary restitution power, the FTC can stop the behavior but cannot compensate the people who were already harmed.
• Watch the other healthcare companies. Both Peyroux and Detelich hold interests in other healthcare entities that are named in the court record but not shut down by this order. Monitor state licensing databases and FTC public records for future enforcement actions involving their names or associated entities.